57.29
前日終値:
$58.79
開ける:
$58.74
24時間の取引高:
1.27M
Relative Volume:
0.92
時価総額:
$7.58B
収益:
$947.36M
当期純損益:
$392.47M
株価収益率:
18.97
EPS:
3.02
ネットキャッシュフロー:
$392.71M
1週間 パフォーマンス:
-6.68%
1か月 パフォーマンス:
-12.08%
6か月 パフォーマンス:
+10.66%
1年 パフォーマンス:
+48.27%
Halozyme Therapeutics Inc Stock (HALO) Company Profile
名前
Halozyme Therapeutics Inc
セクター
電話
(858) 794-8889
住所
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
HALO
Halozyme Therapeutics Inc
|
57.29 | 7.58B | 947.36M | 392.47M | 392.71M | 3.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-10-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2024-09-19 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-06-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
2024-02-29 | 開始されました | TD Cowen | Outperform |
2023-07-24 | ダウングレード | Goldman | Buy → Neutral |
2023-07-24 | 開始されました | H.C. Wainwright | Buy |
2023-05-10 | アップグレード | Piper Sandler | Neutral → Overweight |
2023-03-27 | 再開されました | Berenberg | Buy |
2023-03-16 | ダウングレード | SVB Securities | Outperform → Market Perform |
2022-12-21 | 再開されました | Morgan Stanley | Overweight |
2022-11-28 | 開始されました | Wells Fargo | Overweight |
2022-09-09 | 開始されました | Morgan Stanley | Overweight |
2022-05-23 | 開始されました | SVB Leerink | Outperform |
2021-06-14 | 開始されました | Evercore ISI | Outperform |
2021-05-17 | 開始されました | SVB Leerink | Outperform |
2021-05-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
2021-01-21 | 繰り返されました | The Benchmark Company | Buy |
2020-12-17 | 開始されました | Berenberg | Buy |
2020-09-14 | 再開されました | JP Morgan | Overweight |
2020-07-01 | 開始されました | The Benchmark Company | Buy |
2020-02-05 | アップグレード | Piper Sandler | Neutral → Overweight |
2020-01-09 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2020-01-08 | 開始されました | Goldman | Buy |
2019-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
2018-10-19 | 再開されました | Piper Jaffray | Neutral |
2018-05-11 | ダウングレード | Barclays | Equal Weight → Underweight |
2018-01-24 | 開始されました | Goldman | Neutral |
2017-10-16 | 繰り返されました | Piper Jaffray | Overweight |
2017-01-06 | ダウングレード | Citigroup | Buy → Neutral |
2016-11-03 | 開始されました | Deutsche Bank | Buy |
2015-12-04 | 開始されました | Wells Fargo | Outperform |
2015-11-18 | 開始されました | Citigroup | Buy |
2015-09-22 | 開始されました | Barclays | Overweight |
2015-06-22 | 繰り返されました | JP Morgan | Overweight |
2015-03-03 | 繰り返されました | UBS | Buy |
2015-02-18 | 繰り返されました | MLV & Co | Buy |
2015-01-08 | 繰り返されました | MLV & Co | Buy |
すべてを表示
Halozyme Therapeutics Inc (HALO) 最新ニュース
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet - simplywall.st
If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity - Yahoo Finance
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market - MSN
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Pre - GuruFocus
Peering Into Halozyme Therapeutics's Recent Short Interest - Benzinga
Argenx stock rises on FDA nod for Vyvgart Hytrulo (ARGX) - Seeking Alpha
Halozyme Therapeutics Reports FDA Approval for Self-Injectable Syringe Developed in Partnership With Argenx - marketscreener.com
Halozyme :FDA Oks Argenx' VYVGART Hytrulo Prefilled Syringe For Generalized Myasthenia Gravis & CIDP - Nasdaq
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - Citizen Tribune
J&J, Halozyme win EU nod for injectable Rybrevant in lung cancer - MSN
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewswire Inc.
Game-Changing FDA Approval: New Self-Injectable Treatment Transforms Rare Disease Care - Stock Titan
Halozyme Therapeutics (HALO) Gains EU Approval for Injectable Co - GuruFocus
J&J, Halozyme get EU nod for Darzalex SC to treat multiple myeloma - Seeking Alpha
European Commission Approved Subcutaneous Darzalex (Daratumumab) Based Quadruplet Regimen - marketscreener.com
Halozyme Reports EC Approval For Indication Extension Of DARZALEX Co-formulated With ENHANZE - Nasdaq
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - Quantisnow
Halozyme Therapeutics : Announces Roche Receives FDA Approval For Phesgo™ (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing 's ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Bre - MarketScreener
Halozyme Therapeutics : To Receive $10 Million Milestone Payment From Janssen - MarketScreener
Halozyme (HALO) Secures European Approval for J&J Antitumor Inje - GuruFocus
EC approves new lung cancer treatment using Halozyme technology By Investing.com - Investing.com South Africa
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - The Malaysian Reserve
Halozyme Says EC Approved Subcutaneous Rybrevant For Advanced EGFR-Mutated NSCLC - Nasdaq
EC approves new lung cancer treatment using Halozyme technology - Investing.com
European Commission Approves Subcutaneous Rybrevant® (Amivantamab) - MarketScreener
KLP Kapitalforvaltning AS Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock - Investing.com Australia
Halozyme Therapeutics director Jeffrey Henderson sells $32,217 in stock By Investing.com - Investing.com South Africa
4,812 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by EntryPoint Capital LLC - MarketBeat
Corebridge Financial Inc. Has $9.81 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Long Term Trading Analysis for (HALO) - news.stocktradersdaily.com
Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method - Nasdaq
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications - Quantisnow
Major Breakthrough: New Cancer Drug Delivery Method Gets EU Panel Support - Stock Titan
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Merck plans to launch US subcutaneous version of Keytruda on October 1 - Reuters
Halozyme Therapeutics (HALO) Stock Price, News & Analysis - MarketBeat
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Halozyme stock soars to all-time high of $65.54 By Investing.com - Investing.com South Africa
Halozyme stock soars to all-time high of $65.54 - Investing.com India
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick - Yahoo Finance
Halozyme Announces Retirement of Chief Technical Officer - TipRanks
Halozyme announces CTO retirement, effective immediately - Investing.com India
Halozyme announces CTO retirement, effective immediately By Investing.com - Investing.com Australia
Drug developers show mixed performance in early 2025 - BioWorld MedTech
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Halozyme Joins the $1 Billion Club - Yahoo Finance
AstraZeneca signs $1.35B Alteogen deal for subcutaneous cancer drugs - Fierce Pharma
Halozyme Therapeutics: Steady Growth In A Challenged Market (NASDAQ:HALO) - Seeking Alpha
Halozyme Therapeutics Inc (HALO) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):